Cargando…
Association between sacubitril/valsartan initiation and real‐world health status trajectories over 18 months in heart failure with reduced ejection fraction
AIMS: Improving the health status (symptoms, function, and quality of life) of patients with heart failure with reduced ejection fraction (HFrEF) is a primary treatment goal. Angiotensin receptor neprilysin inhibitors (ARNI) improve short‐term health status in clinical practice, but the sustainabili...
Autores principales: | Thomas, Merrill, Khariton, Yevgeniy, Fonarow, Gregg C., Arnold, Suzanne V., Hill, Larry, Nassif, Michael E., Chan, Paul S., Butler, Javed, Thomas, Laine, DeVore, Adam D., Hernandez, Adrian F., Albert, Nancy M., Patterson, J. Herbert, Williams, Fredonia B., Spertus, John A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8318450/ https://www.ncbi.nlm.nih.gov/pubmed/33932120 http://dx.doi.org/10.1002/ehf2.13298 |
Ejemplares similares
-
Heterogeneity of health status treatment response with sacubitril/valsartan: insights from the CHAMP‐HF registry
por: Khariton, Yevgeniy, et al.
Publicado: (2020) -
Identifying patients at increased risk for poor outcomes from heart failure with reduced ejection fraction: the PROMPT‐HF risk model
por: DeVore, Adam D., et al.
Publicado: (2021) -
Health Status Disparities by Sex, Race/Ethnicity, and Socioeconomic Status in Outpatients With Heart Failure
por: Khariton, Yevgeniy, et al.
Publicado: (2018) -
Angiotensin Receptor Neprilysin Inhibition and Associated Outcomes by Race and Ethnicity in Patients With Heart Failure With Reduced Ejection Fraction: Data From CHAMP‐HF
por: Chapman, Brittany, et al.
Publicado: (2022) -
Characteristics and Treatments of Patients Enrolled in the CHAMP‐HF Registry Compared With Patients Enrolled in the PARADIGM‐HF Trial
por: DeVore, Adam D., et al.
Publicado: (2018)